Abstract 189P
Background
NF-κB-interacting LncRNA (NKILA) plays an inhibitory role in the NF-κB pathway, which is a key regulator of inflammatory cytokines. These mediators, freely floating in ascitic fluid (AF), reflecting the molecular genetic characteristics of tumor cells in ovarian cancer (OC), and associated with epigenetic switches of key pathways of carcinogenesis remain poorly understood. The aim of the work was to study the expression of LncRNA NKILA and marker cytokines of the NF-kB pathway in ascites of patients with OC.
Methods
The study included 22 patients with ascitic OC at stage III-IV according to FIGO. Isolation of circulating nucleic acid was performed from 2 ml of the cell-free fraction of ascites before treatment using SileksMagNaDirect magnetic particles (Sileks, Russia). lncRNA NKILA expression in AF was determined by qPCR (CFX-96, BioRad). Determination of cytokines VEGFA, IL-6, MCP-1 in AF was performed by ELISA. According to the effect of platinum-containing chemotherapy (CT), the patients were divided into groups: 1 - progression against the background of CT and early relapse; 2 - nonrelapsive. Statistical data processing was carried out using Statistica 13.0.
Results
The study included 22 patients with ascitic OC at stage III-IV according to FIGO. Isolation of circulating nucleic acid was performed from 2 ml of the cell-free fraction of ascites before treatment using SileksMagNaDirect magnetic particles (Sileks, Russia). lncRNA NKILA expression in AF was determined by qPCR (CFX-96, BioRad). Determination of cytokines VEGFA, IL-6, MCP-1 in AF was performed by ELISA. According to the effect of platinum-containing chemotherapy (CT), the patients were divided into groups: 1 - progression against the background of CT and early relapse; 2 – non-relapsive. Statistical data processing was carried out using Statistica 13.0.
Conclusions
Thus, the study of the lncRNA NKILA profile in tumor ascites in relation to inflammatory cytokines of the NF-kB signaling pathway requires further study in the context of understanding the signatures in the formation of chemoresistance in advanced OC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
150P - Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Presenter: Ravindran Kanesvaran
Session: Poster viewing 03
Resources:
Abstract
Slides
151P - Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: Real-world analysis of chemotherapy use and impact on patient outcomes
Presenter: Alison Hiong
Session: Poster viewing 03
152P - An epidemiologic study on PD-L1 expression with clinical observation of initial treatment pattern in the Chinese muscle invasive urothelial bladder carcinoma patients
Presenter: Liqun Zhou
Session: Poster viewing 03
153P - Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
Presenter: Tiago Padua
Session: Poster viewing 03
154P - Can urine cytology predict variants of bladder cancer?
Presenter: Hikaru Mikami
Session: Poster viewing 03
155P - Search for circulating tumor cells in patients with urothelial cancer
Presenter: Irina Kruglova
Session: Poster viewing 03
156P - The association between response to enfortumab vedotin therapy and primary tumor location in Japanese urothelial carcinoma patients
Presenter: Nozomi Hayakawa
Session: Poster viewing 03
163P - Outcomes and toxicity of fosfesterol in metastatic castration-resistant prostate cancer: Experience from a low middle income country
Presenter: Manuprasad Avaronnan
Session: Poster viewing 03
164P - F-18 PSMA-PET/CT-guided percutaneous prostate biopsy
Presenter: Rajender Kumar
Session: Poster viewing 03
165P - Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Presenter: Richard Kelly
Session: Poster viewing 03